NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today the appointment of David Wambeke as Chief Business Officer, effective March 1, 2026. In conjunction with his appointment, Mr. Wambeke purchased 1,000,000 shares of NeuroOne common stock at $0.6704 per share, representing the closing price on February 27, 2026. This insider purchase aligns his interests with shareholders and demonstrates strong conviction in the company's strategic direction.
Mr. Wambeke will lead NeuroOne’s drug delivery program and collaborate with the executive team to advance clinical development and commercialization. His responsibilities include refining product requirements for preclinical and clinical-stage devices, expanding relationships with key opinion leaders, and engaging prospective pharmaceutical partners to maximize the value of the company's emerging drug delivery platform. He will also oversee investor relations and support strategic business development initiatives, including partnerships and corporate transactions.
“David brings a rare combination of public company experience, capital markets expertise, and a demonstrated ability to translate strategic vision into operational and clinical execution,” said Dave Rosa, CEO of NeuroOne. “As we continue to execute on our strategy and expand awareness of NeuroOne’s technology platform, we believe David will be instrumental in sharpening our messaging, deepening investor engagement, and advancing business development activities that support long-term value creation.”
Mr. Wambeke previously served as Chief Business Officer at DiaMedica Therapeutics, where he led the strategic expansion of a lead biologic into preeclampsia, overseeing a first-in-pregnancy Phase 2 clinical trial that delivered positive results. Prior to DiaMedica, he spent approximately 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising healthcare companies on equity financings, M&A, and strategic transactions. He began his career in the U.S. Army and was awarded the Purple Heart after being wounded in combat in Baghdad, Iraq.
“I’m excited to join NeuroOne at such a pivotal moment and to meaningfully align myself with shareholders through my investment,” said Mr. Wambeke. “With four FDA 510(k)-cleared devices and a strategic partnership with Zimmer Biomet, NeuroOne has validated its platform technology and established a strong commercial foundation in epilepsy and trigeminal nerve applications. As the Company continues to scale commercialization across these cleared indications, I believe even greater opportunities lie ahead in basivertebral ablation, drug delivery, and spinal cord stimulation.”
NeuroOne intends to use the net proceeds from the share sale to support ongoing clinical and product development activities, working capital, and general corporate purposes. The shares sold to Mr. Wambeke were not registered under the Securities Act and were issued in a private placement. Additionally, the company granted Mr. Wambeke an inducement stock option to purchase 500,000 shares under the NeuroOne 2021 Inducement Plan, with an exercise price of $0.6704 per share, vesting over four years. This grant was a material inducement to his employment, approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
NeuroOne focuses on improving surgical care for neurological disorders, marketing minimally invasive electrode technology with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System, and OneRF Trigeminal Nerve Ablation System. The company is also researching drug delivery and spinal cord stimulation programs. For more information, visit nmtc1.com.
